Drug Trial Radar · NCT00429273
Single Versus Combination Medication Treatment for Children With Attention Deficit Hyperactivity Disorder
Last checked: Nov 19, 2026Latest source record: Jul 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
212
Actual
Start
Jan 2007
Primary completion
Jul 2011
Study completion Jul 2011
Sponsor
- Lead sponsor
- University of California, Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- First posted
- Jan 31, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 7 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the effectiveness of a single drug versus a combination of drugs in treating attention deficit hyperactivity disorder in children.
Conditions
- Attention Deficit Disorder With Hyperactivity
Interventions
GuanfacineDrug
Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
Methylphenidate (MPH)Drug
Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ADHD IV Rating Scale (Attention Deficit Hyperactivity Disorder Rating Scale)Time frame: Measured at baseline Week 4 and Week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.